NOD2 and inflammatory bowel disease: A recent analysis of the effect of NOD2 homozygotes and compound heterozygotes compared to wild type NOD2 homozygotes in CD patients in clinical remission and in non-IBD controls detected no significant differences in the fecal microbiota [75].